Allergan ROE 2006-2018 | AGN

Current and historical return on equity (ROE) values for Allergan (AGN) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Allergan ROE for the three months ending September 30, 2018 was 8.44%.
Allergan ROE - Return on Equity Historical Data
Date TTM Net Income Shareholder's Equity Return on Equity
2018-09-30 $2.21B $70.52B 3.07%
2018-06-30 $-1.78B $71.26B -2.47%
2018-03-31 $-2.10B $72.35B -2.87%
2017-12-31 $-4.40B $73.84B -5.96%
2017-09-30 $-7.53B $71.17B -10.11%
2017-06-30 $11.65B $75.23B 14.73%
2017-03-31 $11.87B $75.20B 14.95%
2016-12-31 $14.70B $76.20B 18.37%
2016-09-30 $14.06B $89.73B 17.56%
2016-06-30 $4.15B $76.64B 5.38%
2016-03-31 $4.40B $77.45B 5.80%
2015-12-31 $3.68B $76.59B 4.95%
2015-09-30 $3.65B $77.48B 5.86%
2015-06-30 $-2.62B $72.08B -5.22%
2015-03-31 $-2.26B $71.41B -6.53%
2014-12-31 $-1.63B $28.34B -8.49%
2014-09-30 $-1.05B $29.15B -7.21%
2014-06-30 $0.06B $9.69B 0.79%
2014-03-31 $-0.55B $9.63B -8.32%
2013-12-31 $-0.75B $9.54B -14.67%
2013-09-30 $-0.57B $3.75B -15.55%
2013-06-30 $-0.56B $3.54B -15.31%
2013-03-31 $-0.06B $3.62B -1.63%
2012-12-31 $0.10B $3.86B 2.65%
2012-09-30 $0.17B $3.69B 4.56%
2012-06-30 $0.16B $3.56B 4.37%
2012-03-31 $0.27B $3.66B 7.64%
2011-12-31 $0.26B $3.56B 7.51%
2011-09-30 $0.18B $3.49B 5.41%
2011-06-30 $0.14B $3.47B 4.26%
2011-03-31 $0.16B $3.37B 4.92%
2010-12-31 $0.19B $3.28B 5.81%
2010-09-30 $0.22B $3.22B 7.18%
2010-06-30 $0.26B $3.14B 9.03%
2010-03-31 $0.24B $3.09B 9.12%
2009-12-31 $0.22B $3.02B 9.13%
2009-09-30 $0.22B $2.31B 10.03%
2009-06-30 $0.23B $2.23B 10.71%
2009-03-31 $0.24B $2.16B 11.38%
2008-12-31 $0.24B $2.11B 11.85%
2008-09-30 $0.22B $2.05B 11.32%
2008-06-30 $0.18B $1.97B 9.78%
2008-03-31 $0.16B $1.90B 8.74%
2007-12-31 $0.14B $1.85B 7.90%
2007-09-30 $-0.39B $1.81B -22.16%
2007-06-30 $-0.39B $1.77B -21.12%
2007-03-31 $-0.44B $1.71B -22.82%
2006-12-31 $-0.45B $1.68B -21.97%
2006-09-30 $0.06B $2.17B 2.95%
2006-06-30 $0.07B $2.13B 3.22%
2006-03-31 $0.12B $2.14B 5.85%
2005-12-31 $0.14B $2.10B 6.45%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $51.409B $15.941B
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.738B 6.05
Mylan (MYL) United Kingdom $15.753B 6.49
Bausch Health Cos (BHC) Canada $8.275B 5.99
Dr Reddy's Laboratories (RDY) India $6.267B 24.99
Supernus Pharmaceuticals (SUPN) United States $1.909B 18.08
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.730B 2.88
Amphastar Pharmaceuticals (AMPH) United States $1.014B 109.95
Homology Medicines (FIXX) United States $0.937B 0.00
Assembly Biosciences (ASMB) United States $0.634B 0.00
Akorn (AKRX) United States $0.535B 0.00
CymaBay Therapeutics (CBAY) United States $0.511B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.386B 0.00
Voyager Therapeutics (VYGR) United States $0.349B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.273B 0.00
Sol-Gel Technologies (SLGL) Israel $0.118B 0.00
Teligent (TLGT) United States $0.086B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.085B 0.00
Aevi Genomic Medicine (GNMX) United States $0.077B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.054B 0.00
Acasti Pharma (ACST) Canada $0.052B 0.00
Evoke Pharma (EVOK) United States $0.046B 0.00
Agile Therapeutics (AGRX) United States $0.028B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.005B 0.00